<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511676</url>
  </required_header>
  <id_info>
    <org_study_id>LEV-HD</org_study_id>
    <nct_id>NCT04511676</nct_id>
  </id_info>
  <brief_title>The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis</brief_title>
  <official_title>The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phramongkutklao College of Medicine and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Silpakorn University Faculty of Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Phramongkutklao College of Medicine and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Levetiracetam (LEV) is one of second-generation antiepileptic drugs that has been used to&#xD;
      treat partial and generalized epilepsy. LEV is eliminated from the systemic circulation by&#xD;
      renal excretion. Therefore, patients with renal impairment may experience a reduced drug&#xD;
      excretion and increased adverse drug reactions. Moreover, patients with end-stage renal&#xD;
      disease who need dialysis may experience low serum LEV concentration because of drug loss via&#xD;
      dialysis. LEV loss via dialysis can cause low serum level of LEV that insufficient for&#xD;
      seizure control. The present study was aimed to evaluate pharmacokinetics of LEV in patients&#xD;
      undergoing 4 hour-intermittent hemodialysis (IHD). The results of the study may benefit to&#xD;
      determine the appropriate LEV initial dose and supplemental dose for patients undergoing IHD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">October 10, 2019</completion_date>
  <primary_completion_date type="Actual">October 10, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of Levetiracetam</measure>
    <time_frame>Immediately before an initiation of an intermittent hemodialysis session</time_frame>
    <description>Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on dialysis day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Levetiracetam</measure>
    <time_frame>1 hour after an initiation of an intermittent hemodialysis session</time_frame>
    <description>Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on dialysis day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Levetiracetam</measure>
    <time_frame>2 hour after an initiation of an intermittent hemodialysis session</time_frame>
    <description>Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on dialysis day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Levetiracetam</measure>
    <time_frame>3 hour after an initiation of an intermittent hemodialysis session</time_frame>
    <description>Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on dialysis day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Levetiracetam</measure>
    <time_frame>4 hour after an initiation of an intermittent hemodialysis session</time_frame>
    <description>Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on dialysis day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Levetiracetam</measure>
    <time_frame>Before an administration of Levetiracetam post-hemodialysis supplemental dose</time_frame>
    <description>Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on dialysis day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of Levetiracetam</measure>
    <time_frame>1 hour after finishing an administration of Levetiracetam post-hemodialysis supplemental dose</time_frame>
    <description>Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on dialysis day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Levetiracetam</measure>
    <time_frame>Immediately before Levetiracetam administration</time_frame>
    <description>Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on non-dialysis day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Levetiracetam</measure>
    <time_frame>1 hour after finishing Levetiracetam administration</time_frame>
    <description>Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on non-dialysis day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse drug reactions from Levetiracetam</measure>
    <time_frame>From the first day that participants were included to the study and treated with Levetiracetam until the date of the last point of serum Levetiracetam sampling, assessed up to 3 days</time_frame>
    <description>Observed signs and symptoms of Levetiracetam adverse drug reactions after participants were administered with Levetiracetam.</description>
  </secondary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Seizures</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were admitted to Phramongkutklao Hospital as inpatients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who were at least 18 years old.&#xD;
&#xD;
          2. Patients who were diagnosed with seizure.&#xD;
&#xD;
          3. Patients who were undergoing intermittent hemodialysis and were treated with&#xD;
             intravenous Levetiracetam not less than 2 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who were pregnant or lactating&#xD;
&#xD;
          2. Patients who were treated with intravenous Levetiracetam more than once a day&#xD;
&#xD;
          3. Patients who were undergoing sustained low efficiency dialysis (SLED)&#xD;
&#xD;
          4. Patients who have intermittent dialysis duration less than 3 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasiri Sithinamsuwan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pharmongkutklao Hospital and College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daraporn Rungprai, BCP</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Pharmacy, Silpakorn University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juthathip Suphanklang, BCP</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Pharmacy, Silpakorn University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wongsakorn Promken, B Pharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>The College of Pharmacotherapy of Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmongkutklao Hospital</name>
      <address>
        <city>Ratchathewi</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000 Feb;85(2):77-85. Review.</citation>
    <PMID>10722121</PMID>
  </reference>
  <reference>
    <citation>Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43(11):707-24. Review.</citation>
    <PMID>15301575</PMID>
  </reference>
  <reference>
    <citation>Smetana KS, Cook AM, Bastin ML, Oyler DR. Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. J Crit Care. 2016 Dec;36:116-124. doi: 10.1016/j.jcrc.2016.06.023. Epub 2016 Jul 5. Review.</citation>
    <PMID>27546759</PMID>
  </reference>
  <reference>
    <citation>Engelbrecht L, Grobler CJ, Rheeders M. A simple and cost-effective HPLC-UV method for the detection of levetiracetam in plasma/serum of patients with epilepsy. Biomed Chromatogr. 2017 Oct;31(10). doi: 10.1002/bmc.3969. Epub 2017 Apr 20. Review.</citation>
    <PMID>28294369</PMID>
  </reference>
  <reference>
    <citation>Jarvie D, Mahmoud SH. Therapeutic Drug Monitoring of Levetiracetam in Select Populations. J Pharm Pharm Sci. 2018;21(1s):149s-176s. doi: 10.18433/jpps30081. Review.</citation>
    <PMID>30096051</PMID>
  </reference>
  <reference>
    <citation>Yamamoto J, Toublanc N, Kumagai Y, Stockis A. Levetiracetam pharmacokinetics in Japanese subjects with renal impairment. Clin Drug Investig. 2014 Nov;34(11):819-28. doi: 10.1007/s40261-014-0237-7.</citation>
    <PMID>25312351</PMID>
  </reference>
  <reference>
    <citation>Shiue HJ, Taylor M, Sands KA. Comparison of Levetiracetam Dosing Regimens in End-Stage Renal Disease Patients Undergoing Intermittent Hemodialysis. Ann Pharmacother. 2017 Oct;51(10):862-865. doi: 10.1177/1060028017713294. Epub 2017 Jun 5.</citation>
    <PMID>28582998</PMID>
  </reference>
  <reference>
    <citation>Wieruszewski PM, Kashani KB, Rabinstein AA, Frazee E. Levetiracetam Pharmacokinetics in a Critically Ill Anephric Patient on Intermittent Hemodialysis. Neurocrit Care. 2018 Apr;28(2):243-246. doi: 10.1007/s12028-017-0441-4.</citation>
    <PMID>28828726</PMID>
  </reference>
  <reference>
    <citation>Company-Albir MJ, Ruíz-Ramos J, Solana Altabella A, Marqués-Miñana MR, Vicent C, Poveda JL. Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report. J Clin Pharm Ther. 2017 Dec;42(6):774-775. doi: 10.1111/jcpt.12568. Epub 2017 May 28.</citation>
    <PMID>28555936</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Levetiracetam</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

